|
Volumn 3, Issue 3, 2002, Pages 219-228
|
The economic impact of chronic obstructive pulmonary disease
|
Author keywords
Chronic bronchitis; Chronic obstructive pulmonary disease; Economics; Emphysema; Treatment cost
|
Indexed keywords
AMOXICILLIN;
AMOXICILLIN PLUS CLAVULANIC ACID;
ANTIBIOTIC AGENT;
AZITHROMYCIN;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CEFACLOR;
CEFPROZIL;
CEFRADINE;
CEFUROXIME;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
CIPROFLOXACIN;
CORTICOSTEROID;
COTRIMOXAZOLE;
ERYTHROMYCIN;
INFLUENZA VACCINE;
IPRATROPIUM BROMIDE;
METHYLXANTHINE;
OXYGEN;
PNEUMOCOCCUS VACCINE;
SALBUTAMOL;
SALMETEROL;
TETRACYCLINE;
THEOPHYLLINE;
ADULT;
AGED;
CAREGIVER;
CAUSE OF DEATH;
CHRONIC BRONCHITIS;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
ECONOMIC ASPECT;
FEMALE;
HEALTH CARE COST;
HOSPITALIZATION;
HUMAN;
INFLUENZA;
LONG TERM CARE;
LUNG EMPHYSEMA;
MALE;
MORTALITY;
MULTICENTER STUDY;
OXYGEN THERAPY;
PREVALENCE;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
RESOURCE MANAGEMENT;
REVIEW;
SIDE EFFECT;
SMOKING CESSATION;
SOCIAL ASPECT;
STREPTOCOCCUS INFECTION;
UNITED STATES;
ADULT;
ANTI-BACTERIAL AGENTS;
HUMANS;
OXYGEN INHALATION THERAPY;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
SMOKING CESSATION;
TERMINOLOGY;
|
EID: 0036199723
PISSN: 14656566
EISSN: None
Source Type: Journal
DOI: 10.1517/14656566.3.3.219 Document Type: Review |
Times cited : (35)
|
References (57)
|